{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:44:53Z","timestamp":1793231093052,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ensci.2025.100550","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:28Z","timestamp":1736184628000},"page":"100550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications."],"prefix":"10.1016","volume":"38","author":[{"given":"Sara","family":"Samadzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy D.","family":"Sleator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0005","article-title":"A beginner\u2019s guide to genomics in complex neurological disorders","volume":"1","author":"Quirke","year":"2024","journal-title":"Innovation Dscovery"},{"key":"10.1016\/j.ensci.2025.100550_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148198","article-title":"Unravelling the genetic basis of schizophrenia","volume":"902","author":"Casey","year":"2024","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.ensci.2025.100550_bb0015","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s10072-023-07228-3","article-title":"Current use of fluid biomarkers as outcome measures in multiple sclerosis (MS): a review of ongoing pharmacological clinical trials","volume":"45","author":"Schilke","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ensci.2025.100550_bb0020","first-page":"Jco2301621","article-title":"Systematic review of cerebrospinal fluid biomarker discovery in neuro-oncology: a roadmap to standardization and clinical application","author":"Mikolajewicz","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","article-title":"Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold","volume":"37","author":"Krieger","year":"2024","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0035","article-title":"Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches","volume":"1-23","author":"Aliyu","year":"2024","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0040","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00415-023-12021-5","article-title":"Identification and management of subclinical disease activity in early multiple sclerosis: a review","volume":"271","author":"Ontaneda","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","article-title":"Updates in NMOSD and MOGAD diagnosis and treatment: a tale of two central nervous system autoimmune inflammatory disorders","volume":"42","author":"Cacciaguerra","year":"2024","journal-title":"Neurol. Clin."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2020.1764352","article-title":"Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica","volume":"20","author":"Rocca","year":"2020","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.ensci.2025.100550_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.746959","article-title":"Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder activity and severity: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108624","article-title":"Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease - a systematic review","volume":"107","author":"Heimfarth","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.ensci.2025.100550_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274565","article-title":"Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"17","author":"Ning","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ensci.2025.100550_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16284","article-title":"Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: a systematic review and meta-analysis","author":"Hagbohm","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0075","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s10072-023-07277-8","article-title":"Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein","volume":"45","author":"Kim","year":"2024","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0080","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s40120-023-00535-z","article-title":"Neurofilament light chain in adult and pediatric multiple sclerosis: a promising biomarker to better characterize disease activity and personalize MS treatment","volume":"12","author":"Ghezzi","year":"2023","journal-title":"Neurol. Ther."},{"issue":"21","key":"10.1016\/j.ensci.2025.100550_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113466","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein as biomarkers in primary progressive multiple sclerosis and hereditary spastic paraplegia type 4","volume":"23","author":"Kessler","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0090","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamaneurol.2023.0394","article-title":"Challenges and opportunities for the promising biomarker blood Neurofilament light Chain","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.12703\/r\/10-46","article-title":"Neurofilament light: a narrative review on biomarker utility","volume":"10","author":"Narayanan","year":"2021","journal-title":"Fac. Rev."},{"issue":"5","key":"10.1016\/j.ensci.2025.100550_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0105","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"Pt 14","key":"10.1016\/j.ensci.2025.100550_bb0110","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1242\/jcs.104729","article-title":"Neurofilaments at a glance","volume":"125","author":"Yuan","year":"2012","journal-title":"J. Cell Sci."},{"issue":"11","key":"10.1016\/j.ensci.2025.100550_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8110523","article-title":"Blood neurofilament light chain: the neurologist\u2019s troponin?","volume":"8","author":"Thebault","year":"2020","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.ensci.2025.100550_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411624","article-title":"Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges","volume":"24","author":"Coppens","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40001-023-01631-4","article-title":"Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP)","volume":"29","author":"Zheng","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1750-3639.1994.tb00841.x","article-title":"Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors","volume":"4","author":"Laping","year":"1994","journal-title":"Brain Pathol."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0140","first-page":"3","article-title":"Glial fibrillary acidic protein: the component of intermediate filaments in the vertebrate brain astrocytes","volume":"51","author":"Sukhorukova","year":"2015","journal-title":"Zh. Evol. Biokhim. Fiziol."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1750-3639.1994.tb00838.x","article-title":"GFAP and astrogliosis","volume":"4","author":"Eng","year":"1994","journal-title":"Brain Pathol."},{"issue":"9\u201310","key":"10.1016\/j.ensci.2025.100550_bb0150","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1007677003387","article-title":"Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000)","volume":"25","author":"Eng","year":"2000","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ensci.2025.100550_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.642384","article-title":"The evolution of Neurofilament light Chain in multiple sclerosis","volume":"15","author":"Ferreira-Atuesta","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ensci.2025.100550_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fmicb.2014.00189","article-title":"Combined metagenomic and phenomic approaches identify a novel salt tolerance gene from the human gut microbiome","volume":"5","author":"Culligan","year":"2014","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.ensci.2025.100550_bb0165","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1515\/cclm-2023-0036","article-title":"Neurofilament light chain as neuronal injury marker - what is needed to facilitate implementation in clinical laboratory practice?","volume":"61","author":"Arslan","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"issue":"7","key":"10.1016\/j.ensci.2025.100550_bb0170","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","article-title":"Neurofilaments: neurobiological foundations for biomarker applications","volume":"143","author":"Gafson","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.ensci.2025.100550_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120380","article-title":"Neurofilaments in neurologic disorders and beyond","volume":"441","author":"Mak","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.ensci.2025.100550_bb0180","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1007\/s12035-020-02035-9","article-title":"Different clinical contexts of use of blood Neurofilament light Chain protein in the Spectrum of neurodegenerative diseases","volume":"57","author":"Palermo","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0185","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ensci.2025.100550_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125529","article-title":"Advances in single molecule arrays (SIMOA) for ultra-sensitive detection of biomolecules","volume":"270","author":"Dong","year":"2024","journal-title":"Talanta"},{"issue":"7","key":"10.1016\/j.ensci.2025.100550_bb0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm-19-330","article-title":"Detection and significance of glial fibrillary acidic protein antibody in autoimmune astocytopathy and related diseases","volume":"11","author":"Huang","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ensci.2025.100550_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","article-title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system","volume":"32","author":"Hol","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ensci.2025.100550_bb0205","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of Neuromyelitis Optica Spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.brainres.2014.12.027","article-title":"Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease","volume":"1600","author":"Petzold","year":"2015","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0215","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/brain\/awac328","article-title":"The multifaceted role of neurofilament light chain protein in non-primary neurological diseases","volume":"146","author":"Abu-Rumeileh","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/ane.13415","article-title":"Neurological symptoms and blood neurofilament light levels","volume":"144","author":"Barro","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ensci.2025.100550_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.758182","article-title":"Exploring Neurofilament light Chain and exosomes in the genetic forms of frontotemporal dementia","volume":"16","author":"Zanardini","year":"2022","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/brain\/awad267","article-title":"The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer\u2019s disease","volume":"147","author":"Jung","year":"2024","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0235","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40520-020-01554-8","article-title":"The role of neurofilament light chain in frontotemporal dementia: a meta-analysis","volume":"33","author":"Karantali","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.ensci.2025.100550_bb0240","article-title":"Neurofilament light Chain: a candidate biomarker of perioperative stroke","volume":"14","author":"Zhang","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ana.26860","article-title":"Biomarker qualification for Neurofilament light Chain in amyotrophic lateral sclerosis: theory and practice","volume":"95","author":"Benatar","year":"2024","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.ensci.2025.100550_bb0250","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","article-title":"Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges","volume":"62","author":"Bayoumy","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"10.1016\/j.ensci.2025.100550_bb0255","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0260","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00415-022-11507-y","article-title":"Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis","volume":"270","author":"Sen","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0265","doi-asserted-by":"crossref","first-page":"1382468","DOI":"10.3389\/fneur.2024.1382468","article-title":"A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis","volume":"15","author":"Desu","year":"2024","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0270","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0275","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort","volume":"271","author":"Arroyo Pereiro","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104416","article-title":"Prognostic significance of neurofilament light in Fingolimod therapy for multiple sclerosis: a systemic review and meta-analysis based on randomized control trials","volume":"69","author":"Ashkar","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ensci.2025.100550_bb0285","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jocn.2022.04.041","article-title":"Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: a systematic review and meta-analysis","volume":"101","author":"Liu","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.ensci.2025.100550_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329221","article-title":"Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis","author":"Abdelhak","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.ensci.2025.100550_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8090312","article-title":"Longitudinal serum neurofilament levels of multiple sclerosis patients before and after treatment with first-line immunomodulatory therapies","volume":"8","author":"Huss","year":"2020","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.ensci.2025.100550_bb0300","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209357","article-title":"Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis","volume":"102","author":"Fox","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ensci.2025.100550_bb0305","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light Chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.ensci.2025.100550_bb0310","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and Meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0315","first-page":"101","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","author":"Freedman","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ensci.2025.100550_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103590","article-title":"NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study","volume":"72","author":"Uphaus","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ensci.2025.100550_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103535","article-title":"High or increasing serum NfL is predictive of impending multiple sclerosis relapses","volume":"59","author":"Thebault","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0330","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/13524585211039104","article-title":"Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study","volume":"28","author":"Rosenstein","year":"2022","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.ensci.2025.100550_bb0335","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestr\u00f6m","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0340","first-page":"126","article-title":"Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome","volume":"87","author":"Disanto","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ensci.2025.100550_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102807","article-title":"Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study","volume":"56","author":"Bittner","year":"2020","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0350","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0355","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0360","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.ensci.2025.100550_bb0365","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1177\/13524585221114441","article-title":"Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: analysis from the MS-STAT randomised controlled trial","volume":"28","author":"Williams","year":"2022","journal-title":"Mult. Scler."},{"issue":"13","key":"10.1016\/j.ensci.2025.100550_bb0370","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1177\/1352458519885613","article-title":"Neurofilament light levels are associated with long-term outcomes in multiple sclerosis","volume":"26","author":"Kuhle","year":"2020","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.ensci.2025.100550_bb0375","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.ensci.2025.100550_bb0380","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s00415-019-09477-9","article-title":"Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction","volume":"266","author":"Pedersen","year":"2019","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0385","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000737","article-title":"Serum neurofilament light chain and optical coherence tomography measures in MS: a longitudinal study","volume":"7","author":"Tavazzi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0390","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1177\/1352458520972573","article-title":"Temporal profile of serum neurofilament light in multiple sclerosis: implications for patient monitoring","volume":"27","author":"Calabresi","year":"2021","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0395","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/13524585211032348","article-title":"Sustained reduction of serum neurofilament light chain over 7years by alemtuzumab in early relapsing-remitting MS","volume":"28","author":"Kuhle","year":"2022","journal-title":"Mult. Scler."},{"issue":"21","key":"10.1016\/j.ensci.2025.100550_bb0400","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200258","article-title":"Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials","volume":"98","author":"Leppert","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ensci.2025.100550_bb0405","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000856","article-title":"Long-term prognostic value of longitudinal measurements of blood neurofilament levels","volume":"7","author":"H\u00e4ring","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0410","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ensci.2025.100550_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102463","article-title":"NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS","volume":"46","author":"Novakova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.ensci.2025.100550_bb0420","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0425","first-page":"23","article-title":"Bruton\u2019s tyrosine kinase inhibitors in the treatment of multiple sclerosis","volume":"32","author":"Shulga","year":"2023","journal-title":"Postep. Psychiatr. Neurol."},{"issue":"11\u221212","key":"10.1016\/j.ensci.2025.100550_bb0430","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0435","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.ensci.2025.100550_bb0440","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0445","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ensci.2025.100550_bb0450","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ensci.2025.100550_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105412","article-title":"Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA\u2122, Ella\u2122, and Lumipulse\u2122 in multiple sclerosis na\u00efve patients","volume":"82","author":"Vecchio","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0460","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00068-022-01979-y","article-title":"The diagnostic and prognostic value of glial fibrillary acidic protein in traumatic brain injury: a systematic review and meta-analysis","volume":"49","author":"Pei","year":"2023","journal-title":"Eur. J. Trauma Emerg. Surg."},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0465","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF03256432","article-title":"A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury","volume":"16","author":"Schiff","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ensci.2025.100550_bb0470","series-title":"FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults","year":"2018"},{"key":"10.1016\/j.ensci.2025.100550_bb0475","doi-asserted-by":"crossref","first-page":"1196272","DOI":"10.3389\/fnagi.2023.1196272","article-title":"Research trends and hotspots of glial fibrillary acidic protein within the area of Alzheimer\u2019s disease: a bibliometric analysis","volume":"15","author":"Zou","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0480","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11060-015-1978-8","article-title":"Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma","volume":"126","author":"Tichy","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0485","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-013-1134-2","article-title":"High plasma-GFAP levels in metastatic myxopapillary ependymoma","volume":"113","author":"Ilhan-Mutlu","year":"2013","journal-title":"J. Neuro-Oncol."},{"issue":"8","key":"10.1016\/j.ensci.2025.100550_bb0490","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/glia.23594","article-title":"Importance of GFAP isoform-specific analyses in astrocytoma","volume":"67","author":"van Bodegraven","year":"2019","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0495","doi-asserted-by":"crossref","first-page":"13144","DOI":"10.1038\/s41598-023-39698-y","article-title":"Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19","volume":"13","author":"Bark","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1354750X.2021.2006313","article-title":"Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis","volume":"27","author":"van Asperen","year":"2022","journal-title":"Biomarkers"},{"key":"10.1016\/j.ensci.2025.100550_bb0505","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neulet.2017.07.050","article-title":"GFAP in early multiple sclerosis: a biomarker for inflammation","volume":"657","author":"Kassubek","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0510","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ensci.2025.100550_bb0515","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a Neuromyelitis Optica Spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0520","doi-asserted-by":"crossref","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.ensci.2025.100550_bb0525","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0530","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/revneuro-2020-0145","article-title":"Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis","volume":"32","author":"Momtazmanesh","year":"2021","journal-title":"Rev. Neurosci."},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007624","article-title":"Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage","volume":"4","author":"Linker","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0540","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","article-title":"Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review","volume":"19","author":"Schindler","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.ensci.2025.100550_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020222","article-title":"Neuroinflammation is associated with GFAP and sTREM2 levels in multiple sclerosis","volume":"12","author":"Azzolini","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ensci.2025.100550_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102810","article-title":"Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI","volume":"50","author":"Saraste","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"18","key":"10.1016\/j.ensci.2025.100550_bb0555","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1523\/JNEUROSCI.5480-05.2006","article-title":"Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide","volume":"26","author":"Brahmachari","year":"2006","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0560","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"issue":"11","key":"10.1016\/j.ensci.2025.100550_bb0565","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrgastro.2012.138","article-title":"Novel functional roles for enteric glia in the gastrointestinal tract","volume":"9","author":"Gulbransen","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0570","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/WNL.27.10.911","article-title":"Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis","volume":"27","author":"Whitaker","year":"1977","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ensci.2025.100550_bb0575","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/glia.22443","article-title":"The astrocyte in multiple sclerosis revisited","volume":"61","author":"Brosnan","year":"2013","journal-title":"Glia"},{"issue":"11","key":"10.1016\/j.ensci.2025.100550_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115904","article-title":"Astrocytes in multiple sclerosis-essential constituents with diverse multifaceted functions","volume":"22","author":"Aharoni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ensci.2025.100550_bb0585","article-title":"The role of glial fibrillary acidic protein as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"60","author":"Shaygannejad","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0590","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1007\/s00415-024-12299-z","article-title":"Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury","volume":"271","author":"Schaller-Paule","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0595","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with Neurofilament light Chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.ensci.2025.100550_bb0600","doi-asserted-by":"crossref","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ensci.2025.100550_bb0605","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/WCO.0000000000000676","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"32","author":"Kunchok","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.ensci.2025.100550_bb0610","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000013087","article-title":"Glial fibrillary acidic protein autoimmunity","volume":"98","author":"Gravier-Dumonceau","year":"2022","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ensci.2025.100550_bb0615","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.ensci.2025.100550_bb0620","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41591-024-02938-3","article-title":"An autoantibody signature predictive for multiple sclerosis","volume":"30","author":"Zamecnik","year":"2024","journal-title":"Nat Med"}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650225000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650225000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T16:36:17Z","timestamp":1740760577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650225000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":124,"alternative-id":["S2405650225000048"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2025.100550","relation":{},"ISSN":["2405-6502"],"issn-type":[{"value":"2405-6502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2025.100550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100550"}}